HuMax AXL ADC - GenmabAlternative Names: Axl-specific Antibody-drug Conjugate; HuMax®-AXL-ADC
Latest Information Update: 22 Dec 2016
At a glance
- Originator Genmab; Seattle Genetics
- Developer Genmab
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours